Research Feed
TLX Q4 2025: Trough Valuation With a Ticking Clock
Telix is a radiopharmaceutical company with two businesses: a cash machine (Precision Medicine imaging, $622M revenue, 22% growth) and a free option (therapeutics pipeline, 3 Phase 3 programs, no revenue). Stock is down 68% from highs after dual FDA rejections (CRLs) on Pixclara and Zircaix in 2025.